Blawg Search - Law Blogs, Lawyer Blogs, Legal Blogs Directory & Search Engine

... 's recent $99 million punitive damages judgment against Wyeth Pharmaceuticals Inc., in L. Brocklin v. Wyeth, No. CV04-01701 (October, 15, 2007 ... based company. The punitive damages award came on the heels of what initially appeared to be a victory for Wyeth. Earlier, the jury had reduced its compensatory damages award from $134.5 million ... reach a verdict since the hormone replacement drug trials began last year, with Wyeth winning each of the prior cases at the trial court level. About 5,300 similar ...

Johnson & Johnson's Alza drug unit sued Wyeth (Alza Corporation v. Wyeth, Wyeth Pharmaceuticals, Inc. Case No. 9:06-cv-00156-RHC), saying that Effexor XR infringes a patent for a method of administering antidepressants. Effexor is Wyeth's biggest product and the world's best-selling antidepressant. Global sales of ... says the '457 patent doesn't cover its drug. The patent suit is not the reason Wyeth had "homicidal ideation" added to the drug's label as one of its rare adverse events.

... the powerful drug companies and the FDA's failure in recent years to police the pharmaceutical industry has resulted in more than a few dangerous drugs coming on the market. We ... years before she developed breast cancer in 2002. So far, Pfizer's Wyeth unit has lost 5 of the 8 cases tried with 33 more scheduled for ... birth control drugs, Yaz and Yasmin which were manufactured by Bayer Healthcare Pharmaceuticals, Inc. The Georgia Injury lawyers at Finch McCranie, LLP[www.georgiainjurylawyers.net] have ...

... and Premplus therapy treatments caused breast cancer. Stanway v. Wyeth Canada Inc., 2008 BCSC 847 (June 27, 2008). The company denies the claims ... practices under the province's Business Practices and Consumer Protection Act. Wyeth's motion asserted that the court lacked "territorial competence" over the U.S ... collecting and sharing of other clinical research or trial information, said the Court. Wyeth Pharmaceuticals' role as a central repository and coordinator for adverse event reporting for all ...

... post, we called the kind of Riegel-based arguments that we're seeing in Wyeth's brief "spillover effects." There's another one on page 33 ... obligation." 129 S. Ct. at 1008. After finishing with its preemption by impossibility argument, Wyeth goes on to make the more conventional preemption by obstruction argument that prevailed in Geier v. ... suited to initial determination by the FDA." Id. at 43 (quoting Weinberger v. Bentex Pharmaceuticals, Inc., 412 U.S. 645, 653-654 (1973)). Following a lengthy ...

... included a punitive damages component of over $26 million against defendants Wyeth and Upjohn. Scroggin v. Wyeth (4:04-cv-01169-WRW, E.D. Arkansas)( ... What about unknown causes?) Defendants say this case is the same as Daubert v. Merrell Dow Pharmaceuticals, Inc., 43 F.3d 1311 (9th Cir.), cert. denied, 516 U.S ... be more different. There was also a statute of limitations issue on appeal - the issue was when plaintiff received Wyeth's warning (and, presumably, it would have had to have been sufficient).

... analyst with Sanford C. Bernstein in New York, in a research report. The last big pharmaceutical industry acquisition came in August 2004, when Paris-based Sanofi-Synthelabo acquired ... a 19 percent drop in the Standard & Poor's 500 Pharmaceutical Index. Praise and Concern The Wyeth acquisition has drawn both praise and concern ... smaller potential acquisitions, such as Foster City, California-based Gilead Biosciences Inc., the biggest maker of HIV treatments, would cost less and better enhance ...

... pitched the same point to the Supreme Court in Levine: It is unlikely that judicial adoption of preemption in favor of pharmaceutical manufacturers will result in the wholesale discontinuation of all lawsuits arising from the use of FDA-approved prescription medications. ... of IV injection, but instead chose to preserve the added effectiveness of intravenous administration. . .by requiring Wyeth to include carefully tailored warnings and instructions on the drug's labeling. . . . In this case, a ...

... can make patients suicidal, after judges set trials citing the Wyeth decision. A Barr Pharmaceuticals hyperactivity-drug case is to be tried in August in federal court in Tallahassee ... Supreme Court decided in favor of preemption, it would have sent a strong signal that pharmaceutical failure-to- warn cases were not a profitable place to be" for plaintiffs' lawyers, said ... Glaxo over Paxil and one against New York-based Pfizer Inc. over Zoloft. Drugmakers have not given up on preemption in every case ...

... lawsuits filed against them in federal court in Massachusetts. Pharma giant, Wyeth - poised to be bought out by large pharmaceutical company Pfizer, Inc. later this year - is being accused of overcharging state Medicaid programs by failing ... hopes of making additional profits through outpatient sales. When combined with the rebate allegations being leveraged against the pharmaceutical company, these additional accusations of underhanded marketing tactics make this a case that is sure to be followed ...